Avidity Biosciences, Inc. - Common Stock (RNA)

Historical Holders from Q2 2020 to Q3 2025

Symbol
RNA on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
150M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
161M
Holdings value
$7.01B
% of all portfolios
0.011%
Grand Portfolio weight change
+0.002%
Number of holders
267
Number of buys
189
Number of sells
-70
Average Value change %
+0%
Average buys %
+0.005%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Avidity Biosciences, Inc. - Common Stock (RNA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 9.57% $576M 13.2M The Vanguard Group 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $426M 9.79M T. Rowe Price Associates, Inc. 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 8.1% $300M 9.68M Wellington Management Group LLP 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 5.9% $376M 8.64M RA Capital Management, L.P. 30 Sep 2025
BlackRock, Inc. 6.4% -13.8% $376M -$17.9M 8.63M -4.55% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 5.5% -47.3% $583M -$446M 8.22M -43.4% JANUS HENDERSON GROUP PLC 28 Nov 2025
RTW INVESTMENTS, LP 3.1% $204M 4.69M RTW Investments, LP 27 Oct 2025
FMR LLC 2.1% -86% $129M -$810M 2.96M -86.3% FMR LLC 31 Oct 2025

Institutional Holders of Avidity Biosciences, Inc. - Common Stock (RNA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 161M $7.01B +$1.16B $43.57 267
2025 Q2 136M $3.86B +$69.7M $28.40 205
2025 Q1 133M $3.96B +$178M $29.52 218
2024 Q4 128M $3.71B -$78M $29.08 234
2024 Q3 126M $5.8B +$574M $45.93 240
2024 Q2 112M $4.57B +$938M $40.85 191
2024 Q1 89.3M $2.28B +$376M $25.52 156
2023 Q4 75.9M $687M -$46.2M $9.05 142
2023 Q3 81.7M $522M -$6.43M $6.38 142
2023 Q2 82.4M $914M +$45.8M $11.09 140
2023 Q1 75.9M $1.17B +$49.8M $15.35 138
2022 Q4 71.7M $1.59B +$426M $22.19 148
2022 Q3 53.4M $873M -$22.2M $16.33 121
2022 Q2 52.1M $758M +$70.6M $14.53 107
2022 Q1 47.1M $869M +$27.2M $18.47 98
2021 Q4 45.4M $1.08B +$3.68M $23.77 104
2021 Q3 44.4M $1.09B +$241M $24.63 108
2021 Q2 34.5M $853M +$16.8M $24.71 93
2021 Q1 33.9M $739M +$60.8M $21.81 97
2020 Q4 31M $790M +$74.8M $25.52 82
2020 Q3 27M $755M +$43.8M $28.15 67
2020 Q2 25.5M $702M +$702M $28.26 52